Research Paper Volume 12, Issue 13 pp 13281—13296
SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer
Figure 8. Validation of SLC7A2 based on GEO datasets and clinical samples. mRNA expression levels of SLC7A2 based on (A) GSE27651 (22 high-grade serous ovarian carcinomas and 6 normal ovarian tissues), (B) GSE54388 (16 epithelial ovarian cancer and 6 normal ovarian tissues) and (C) our clinical samples (60 ovarian cancer and 20 normal ovarian tissues). (D) Prognostic significance of SLC7A2 in ovarian cancer based on GSE31245 (58 ovarian cancer cases). ***P < 0.001. GEO, Gene Expression Omnibus.